Page 102 - Read Online

Page 20 of 20 Ma et al. J Cancer Metastasis Treat 2022;8:25 https://dx.doi.org/10.20517/2394-4722.2022.17

PD-1 blockade. Blood 2019;134:1406-14. DOI PubMed PMC
93. Shi Y, Wu J, Wang Z, et al. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an
open-label phase 2 study (Gxplore-002). J Hematol Oncol 2021;14:12. DOI PubMed PMC
94. Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol
2018;11:15. DOI PubMed PMC
95. Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell
lymphoma failing l-asparaginase. Blood 2017;129:2437-42. DOI PubMed
96. Kim SJ, Hyeon J, Cho I, Ko YH, Kim WS. Comparison of efficacy of pembrolizumab between epstein-barr virus-positive and -
negative relapsed or refractory non-hodgkin lymphomas. Cancer Res Treat 2019;51:611-22. DOI
97. Kim SJ, Lim JQ, Laurensia Y, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-
label phase 2 study. Blood 2020;136:2754-63. DOI PubMed
98. Horwitz SM, Feldman TA, Ye JC, et al. Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in
patients with relapsed/refractory peripheral T-Cell lymphoma. Blood 2021;138:622 DOI
99. O’Connor OA, Özcan M, Jacobsen ED, et al. Randomized phase III study of alisertib or investigator’s choice (selected single agent)
in patients with relapsed or refractory peripheral T-Cell lymphoma. J Clin Oncol 2019;37:613-23. DOI PubMed PMC
100. Foss FM, Porcu P, Horwitz SM, et al. A global phase 2 study of valemetostat tosylate (valemetostat) in patients with relapsed or
refractory (R/R) peripheral T-Cell lymphoma (PTCL), including R/R adult T-Cell leukemia/lymphoma (ATL) - valentine-PTCL01.
Blood 2021;138:2533 DOI
101. Yoshimitsu M, Izutsu K, Makita S, et al. Pivotal phase 2 study of the EZH1 and EZH2 inhibitor valemetostat tosylate (DS-3201b) in
patients with relapsed or refractory adult T-Cell leukemia/lymphoma. Blood 2021;138:303-303. DOI
102. Marchi E, Zullo KM, Amengual JE, et al. The combination of hypomethylating agents and histone deacetylase inhibitors produce
marked synergy in preclinical models of T-cell lymphoma. Br J Haematol 2015;171:215-26. DOI PubMed
103. Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter
phase 2 study. Blood 2021;137:2161-70. DOI PubMed
104. Jain S, Jirau-Serrano X, Zullo KM, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent
synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res 2015;21:2096-106. DOI PubMed
105. Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and
refractory T-cell lymphoma. Blood 2018;131:397-407. DOI PubMed PMC
106. Iyer SP, Huen A, Ai WZ, et al. Safety and efficacy of tenalisib given in combination with romidepsin in patients with
relapsed/refractory T-Cell lymphoma: final results from a phase I/II open label multi-center study. Blood 2021;138:1365 DOI
107. Marchi E, Ma H, Montanari F, et al. The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily
treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). JCO 2020;38:8049-8049. DOI
108. Scarfò I, Frigault MJ, Maus MV. CAR-based approaches to cutaneous T-Cell lymphoma. Front Oncol 2019;9:259. DOI PubMed
PMC
109. Biotech L. Legend biotech announces FDA clinical hold of its phase 1 clinical trial for LB1901. Available from:
https://www.businesswire.com/news/home/20220215005555/en/Legend-Biotech-Announces-FDA-Clinical-Hold-of-its-Phase-1-
Clinical-Trial-for-LB1901 [Last accessed on 28 June 2022].
110. Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic,
normal, and neoplastic T-cells. Leukemia 2018;32:2307-15. DOI PubMed PMC
111. Hucks GE, Savoldo B, Dotti G, et al. CD30-directed chimeric antigen receptor (CAR)-T cells for treatment of hodgkin lymphoma
and non-hodgkin lymphoma in pediatric patients. Blood 2021;138:2829. DOI
112. Non-Hodgkin’s Lymphoma Pathologic Classification Project. National cancer institute sponsored study of classifications of non-
hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35. DOI
PubMed
113. Choi S, Pegues MA, Lam N, Geldres C, Vanasse D, Kochenderfer JN. Design and assessment of novel anti-cd30 chimeric antigen
receptors with human antigen-recognition domains. Hum Gene Ther 2021;32:730-43. DOI PubMed PMC
114. Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma. J Clin
Oncol 2020;38:3794-804. DOI PubMed PMC